Search

Displaying results 2311 - 2320 of 10000 in total
  1. Drug

    Labetalol

    go.drugbank.com/drugs/DB00598
    ApprovedInvestigational

    [L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]

    Products: Labetalol HCl in Dextrose, Labetalol HCl in Sodium Chloride
  2. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … [A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations

  3. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties.

  4. Drug

    Picolinic acid

    go.drugbank.com/drugs/DB05483
    Experimental

    Picolinic acid has been shown to be an anti-viral in vitro and in vivo, and sometimes works in conjunction with other cytokines such as interferon gamma to affect immune responses. … It acts as an anti-infective and immunomodulator and is produced in approximately 25-50 mg quantities by the body on a daily basis through the breakdown of tryptophan.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.

  6. Drug

    Treprostinil

    go.drugbank.com/drugs/DB00374
    ApprovedInvestigational

    [L41860] It is available in the following routes of administration: subcutaneous, intravenous, inhaled and oral. The first generic form of treprostinil became available in 2019.[A248775] … Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension.

  7. Drug

    Cocoa butter

    go.drugbank.com/drugs/DB11086
    Approved

    in the first trimester [A33031]. … Cocoa butter is an edible natural fat obtained from the _Theobroma cocoa_ seeds that is predominantly found in dark chocolate [A33033].

    Products: Coconut Cosmetics 3-in-1 Serum
  8. Drug

    Fibrinogen human

    go.drugbank.com/drugs/DB09222
    ApprovedInvestigational

    It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting. … It is indicated for the treatment of acute bleeding episodes in patients with both acquired and congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.[L41065]

  9. Drug

    Metipranolol

    go.drugbank.com/drugs/DB01214
    ApprovedWithdrawn

    It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

  10. Drug

    Piperazine

    go.drugbank.com/drugs/DB00592
    ApprovedVet approvedWithdrawn

    Piperazine was first introduced as an anthelmintic in 1953. … First used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953.